Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab: A case report
作者机构：Department of Radioactive InterventionEastern Hepatobiliary Surgery HospitalThe Second Military Medical UniversityShanghai 200438China Zhongshan Hospital Qingpu BranchFudan UniversityShanghai 200092China Department of Laboratory MedicineShanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai 200080China
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2021年第9卷第10期
页 面：2281-2288页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：National Natural Science Foundation of China No.31971249
主 题：Undifferentiated embryonal sarcoma of the liver Pembrolizumab Programmed cell death protein 1 Tumor mutation burden Immunohistology Case report
摘 要：BACKGROUND Undifferentiated embryonal sarcoma of the liver(UESL)is a neoplasm that rarely develops in *** main treatments for UESL are upfront gross total surgical resection and adjuvant multiagent ***,we report a case of recurrent UESL in an adult treated with pembrolizumab and discuss a method to identify proper candidates for antibody of programmed cell death protein 1(anti-PD-1)*** SUMMARY A 69-year-old woman was admitted for abdominal pain that developed for 1 *** tomography showed a 16 cm mass in the right lobe of the *** hemihepatectomy and lymphadenectomy were performed,and histological diagnosis was *** months later,the patient suffered from painless obstructive jaundice,and positron emission tomography-computed tomography revealed multiple ***,percutaneous transhepatic cholangial drainage was applied to reduce jaundice,and radiofrequency ablation was used to control the lesion near the hepatic ***,the patient suffered from a serious fever caused by the *** patient received treatment with pembrolizumab,and the prescribed dosage was 2 mg/kg every 3 *** the seventh dose,positron emission tomography-computed tomography revealed that the multiple metastases had nearly *** exam was used to evaluate the disease state,and no new lesions were ***-generation sequencing and immunohistology were applied to determine the reason why the patient had such a favorable response to *** mutation burden,microsatellite instability,and programmed death ligand 1 expression can be combined to predict the effect of PD-1 antibodies. When every one of thesebiomarkers are detected in a tumor patient, the patient may be a proper candidatefor PD-1 *** Anti-PD-1 treatment for tumors needs further research to identify indications andproper biomarkers.
维普期刊数据库